Dr. Qiancheng Shen, CEO of Nutshell Therapeutics, holds a Ph.D. from the Shanghai Institute of Materia Medica and brings a robust interdisciplinary background in biology, computational chemistry, and artificial intelligence. She spearheads the company's overarching vision, driving corporate strategy, operations, team expansion, fundraising, and business development. Operating from a 1,500-square-meter R&D center in Shanghai, Nutshell Therapeutics is powered by a multidisciplinary team of experts across biology, chemistry, pharmacology, physics, and AI, drawing top-tier talent from leading multinational pharmaceutical and technology companies. At the core of the company's innovation is AlloStar, a proprietary, AI-driven small-molecule allosteric drug discovery platform designed to tackle previously undruggable targets. Leveraging this platform, Nutshell Therapeutics has built a highly competitive pipeline of therapeutics for oncology and chronic diseases, with its lead asset currently advancing through Phase I clinical trials in both the United States and China.